Search for a trial

Individual albuminuria lowering response to dapagliflozin in a decentralized
clinical trial in patients with type 2 diabetes mellitus and elevated albuminuria

Primary: To determine the individual response to the SGTL2 inhibitor dapagliflozin in urine albumin-to-creatinine ratio (UACR) Secondary:- To determine the individual response to the SGLT2 inhibitor dapagliflozin in: - Systolic blood pressure - Body…

A study of non-invasive diagnostic techniques in renal osteodystrophy: 18F-sodiumfluoride positron emission tomography and serum non-oxidized PTH compared to bone histomorphometry

To assess accuracy of 18F-sodiumfluoride (NaF) positron emission tomography (PET) and serum non-oxidized parathyroid hormone (PTH) as an accurate, reliable and easy applicable diagnostic tools for the assessment of bone turnover in chronic kidney…

EFFECTS OF ANTIBODY REMOVAL BY IMMUNOADSORPTION ON THE IMMUNE PHENOTYPE IN PATIENTS WITH ANTIBODY MEDIATED DISEASES - A *TARGET-TO-B* STUDY

1) To study the effects of antibody removal by immunoadsorption on the immune phenotype over time in patients with B-cell related autoimmune diseases such as MG, AAV, anti-GBM disease, cryoglobulinemic vasculitis and other refractory antibody-…

A single-center, prospective, placebo-controlled, double-blind, randomized, cross-over mechanistic intervention study to investigate the effect of empagliflozin on kidney function in people with either preserved or impaired kidney function with or without type 2 diabetes

We aim to investigate the renal hemodynamic effects of empagliflozin in people with either preserved or impaired renal function with T2DM and people with impaired renal function without T2DM, all with and without adenosine blockade.

A multi-center, randomized, double-blind, placebocontrolled, parallel group, phase III study to
evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients

This study has been transitioned to CTIS with ID 2024-511067-29-00 check the CTIS register for the current data. The purpose of the study is to evaluate the efficacy and safety of LNP023 compared to placebo on proteinuria reduction and slowing renal…

A randomized, double-blind, parallel group, placebo-controlled, multi-center study to assess the safety and tolerability of monthly subcutaneous administrations of a low and high dose cohort of Osocimab to ESRD patients on regular hemodialysis.

In this study researchers want to learn about the safety of drug Osocimab at low and high doses in adult participants with kidney disease undergoing regular dialysis. Patients with kidney disease undergoing regular dialysis are at high risk for…

Determinants of salt taste in healthy volunteers and patients with chronic kidney disease

To compare salt taste and saliva characteristics in healthy volunteers and patients with CKD.

A Randomized, Double-Blind, Placebo-Controlled, Two-Arm Parallel-Group, Multi-Center Phase 3 Pivotal Trial to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients with Sepsis-Associated Acute Kidney Injury

PRIMARYTo demonstrate an effect of recAP on 28-day all-cause mortality.SECONDARY1. To investigate the effect of recAP on long-term Major Adverse Kidney Events (MAKE).2. To investigate the effect of recAP on use of organ support, i.e., mechanical…

*Randomized controlled prospEctiVe trial comparing extended-release with immediate-release tacrOlimus; reducing calcineurin inhibitor related toxicity in LUng TransplantatION patients*

Primary Objective: to show a reduction in eGFR decline in patients treated with LCP tacrolimus compared to IR tacrolimus. Secondary objectives will include investigating the potential decline in other known side effects of calcineurin inhibitors i.e…

Wishing to decrease Aquaresis in ADPKD patients Treated with a V2Ra; the Effect of Regulating protein and salt

To demonstrate the effect of salt and/or protein intake on aquaresis in patients with ADPKD who are treated with a vasopressin V2 receptor antagonist as measured by 24-hour urine volume.

A phase 4, monocenter, randomized, double-blind, placebo-controlled, 4-armed cross-over mechanistic intervention study to assess the renal hemodynamic effect of mono- and combination therapy with empagliflozin (SGLT-2 inhibitor) and losartan (RAS inhibitor) in metformin and/or SU-treated patients with type 2 diabetes mellitus

Investigate the effects of 7 (+-1) days of of mono- and combination therapy with the SGLT2 inhibitor empagliflozin (10 mg QD) and RAS inhibitor losartan (50 mg QD) on renal hemodynamics, (glomerular filtration rate (GFR) / effective renal plasma…

Intracellular levels of magnesium and phosphate in patients with renal hypomagnesemia and hypophosphatemia: a pilot observational study

- To evaluate the effect of magnesium and phosphate supplementation on intracellular levels of magnesium and phosphate determined with different techniques.- To determine if symptoms are related to intracellular levels of magnesium or phosphate.

Canagliflozin REnal Distribution Intervention Trial (CREDIT); A feasibility study for the use of 18F-canagliflozin to quantify individual differences in target-site exposure in diabetes patients

The main objectives are:• To assess canagliflozin target (i.e. receptor) specific binding in vivo• To assess receptor occupancy of canagliflozin in vivo• To determine optimal scanning time in vivoTo explore the relationship between canagliflozin…

Exploratory study into the effect of salt supplementation in Gitelman syndrome

To determine the effect of salt (NaCl) supplementation on (1) physiological parameters (such as serum potassium) and on (2) clinical signs and symptoms and quality of life.

A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of BAY 2327949 in patients with chronic kidney disease (eGFR range from 25 to 60 mL/min/1.73 m²) due to type 2 diabetes or hypertension and at least one cardiovascular comorbidity

To evaluate the efficacy of BAY 2327949 to decrease urine albumin-to-creatinine ratio (UACR) in patients with chronic kidney disease.To evaluate the safety and tolerability of BAY 2327949.